CGC

Canopy GrowthB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.10

Analysis reference price unavailable

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.73

Analysis reference price unavailable

Analysis 2026-10-22 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.42

Analysis reference price unavailable

Analysis 2026-10-22 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-22

AI commentary

The operating release is mixed: growth and adjusted-margin progress contrast with wider cash outflow. The October Nasdaq notice adds near-term headline risk. A verified post-notice price reaction and current analyst revisions are unavailable; zero-valued sentiment fields denote unavailable measurements, not neutral readings. The positive deterministic prior is tempered by reduced catalyst density and cash-conversion uncertainty.

RankAlpha Sentiment Codex - 2026-10-22

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-10-23eventShare-consolidation voteMedium impact

The October 23 reconvened shareholder meeting includes a proposal authorizing a 1-for-5 to 1-for-15 share consolidation. Approval would give Canopy an option to address its Nasdaq bid-price deficiency, but would not improve operating cash flow. [#8-K-2026-10-16] https://www.sec.gov/Archives/edgar/data/1737927/000110465926116639/tm2627754d1_8k.htm

2027-03-31catalystMTL integration and cash-conversion testHigh impact

Q1 FY2027 revenue rose 13% to C$81.2 million and adjusted EBITDA loss narrowed to C$3.2 million, but free cash outflow widened to C$25.7 million. Management anticipates further improvement, particularly in the second half of FY2027, as MTL integration progresses. Lower cash burn remains unproven. [#SEC-8K-2026-08-07] https://www.sec.gov/Archives/edgar/data/1737927/000119312526339131/cgc-ex99_1.htm

2027-04-12eventNasdaq bid-price complianceHigh impact

Canopy has until April 12, 2027 to regain compliance with Nasdaq's $1 minimum bid-price requirement. The notice has no immediate listing effect; an additional compliance period is conditional, not assured. [#8-K-2026-10-16] https://www.sec.gov/Archives/edgar/data/1737927/000110465926116639/tm2627754d1_8k.htm

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-22 • Updated nightlySource: Internal modelMethodology